Heartflow (NASDAQ:HTFL) CFO Vikram Verghese Sells 29,714 Shares

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 29,714 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84. Following the sale, the chief financial officer owned 184,789 shares of the company’s stock, valued at $9,250,537.34. The trade was a 13.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Tuesday, September 15th, Vikram Verghese sold 668 shares of Heartflow stock. The stock was sold at an average price of $50.01, for a total value of $33,406.68.
• On Monday, September 14th, Vikram Verghese sold 4,593 shares of Heartflow stock. The shares were sold at an average price of $50.24, for a total value of $230,752.32.
• On Tuesday, September 8th, Vikram Verghese sold 6,640 shares of Heartflow stock. The shares were sold at an average price of $50.03, for a total value of $332,199.20.
• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Stock Down 2.4%

Shares of HTFL stock opened at $48.33 on Wednesday. The firm has a market capitalization of $4.20 billion and a P/E ratio of -26.41. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $51.78. The stock’s fifty day simple moving average is $36.39 and its 200 day simple moving average is $31.21.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. As a group, equities research analysts expect that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Institutional Trading of Heartflow

Large investors have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new stake in Heartflow in the 2nd quarter valued at about $590,000. Integrated Wealth Concepts LLC bought a new position in Heartflow in the 2nd quarter valued at about $53,000. Squarepoint Ops LLC boosted its stake in Heartflow by 72.0% during the 2nd quarter. Squarepoint Ops LLC now owns 87,052 shares of the company’s stock valued at $2,554,000 after purchasing an additional 36,441 shares during the last quarter. Arizona State Retirement System bought a new stake in Heartflow during the 2nd quarter worth approximately $312,000. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Heartflow in the second quarter worth approximately $1,557,000.

More Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow’s latest quarterly results showed strong operating momentum: revenue rose 47.7% year over year to $64.08 million, while its $0.07-per-share loss was narrower than analysts expected. Heartflow stock and earnings information
• Positive Sentiment: Several institutions recently initiated or increased positions, including Squarepoint Ops, which lifted its stake by 72%, providing a potential source of buying support.
• Positive Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating. UBS set a $55 price target, above the recent trading range, while other firms maintained Buy or Overweight ratings.
• Neutral Sentiment: The CFO’s sales were disclosed as part of a planned trading program, reducing the likelihood that the transactions represent a new negative view of Heartflow’s business. After selling 35,?—actually 35,? shares across September 11–15, CFO Vikram Verghese still owned roughly 179,528 shares.
• Negative Sentiment: CFO Vikram Verghese sold a combined 34,975 shares for approximately $1.75 million at prices near $50 per share, reducing his direct ownership by roughly 16.7% over the reported transactions. CFO SEC filing
• Negative Sentiment: CEO John Farquhar also sold 38,900 shares for approximately $1.82 million on September 10–11 and has reported multiple sales since June. The repeated selling by senior executives, particularly after the stock approached its 52-week high, is likely contributing to short-term pressure. HeartFlow CEO share sale

Analyst Ratings Changes

Several research analysts have commented on the company. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a report on Friday, August 14th. UBS Group started coverage on Heartflow in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 price target for the company. Wells Fargo & Company raised their price objective on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Canaccord Genuity Group upped their target price on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 14th. Finally, Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).